menu search

Sesen bio to conduct additional trial for potential resubmission of vicineum in bladder cancer

Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive ...

December 9, 2021, 1:09 pm

Sesen bio to conduct additional trial for potential resubmission of vicineum in bladder cancer

Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive ...

December 9, 2021, 1:09 pm

Sesen bio to conduct additional trial for potential resubmission of vicineum in bladder cancer

Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive ...

December 9, 2021, 1:09 pm


Search within

Pages Search Results: